Circumventing Gemcitabine resistance in pancreatic cancer using drug delivery systems
Abstract: Gemcitabine is the first line treatment of pancreatic cancer, a treatment that is relying on the expression of human Equilibrative Nucleoside Transporter 1 for cellular uptake. Combined with its short blood half-life and intracellular activation steps, Gemcitabine treatment has many limitations. In this project we tried to circumvent the need for cellular uptake as one step towards increasing the efficiency of Gemcitabine treatment. A liposomal drug delivery system was tested in vitro combined with chemically blocking the uptake route. Because of inconclusive results, the liposomal drug delivery system could not be fully evaluated.
AT THIS PAGE YOU CAN DOWNLOAD THE WHOLE ESSAY. (follow the link to the next page)